



Diagnostics

Test kit for determining the risk of severe

A research group of the Andalusian Public Health System has developed a test kit for diagnosing and predicting severe neurosensory hearing loss in Meniere's disease (MD) patients.



Description

MD is a chronic disorder that affects the inner ear and is determined by genetic, epigenetic and environmental factors. The symptoms are spontaneous episodes of vertigo, ear pressure and hearing loss.

A number of treatments, both clinical and surgical, have come into use, with varying degrees of success in terms of its remission. Currently, these treatments tend to be aggressive, and can even reduce hearing further.

There is currently no technique or biomarker capable of providing an early diagnosis, prognosis or monitoring of the evolution of this disorder.

The research group has developed a gene expression testing kit for diagnosing and predicting the risk of severe neurosensory hearing loss in MD. In addition, the data obtained can serve to monitor the evolution of the disease.

Validation has been based on a cohort of 420 individuals from southeastern Spain (153 diagnosed patients and 276 controls) and another of 293 individuals from Galicia (149 patients and 144 controls).

- 3- Monitor the evolution of the condition.
- 4- Enable the selection of patient groups according to the most appropriate treatment.



Intellectual Property

This technology is protected by patent.



Aims

We are looking for a partner interested in a license and/or a collaboration agreement to further develop and exploit this innovative technology.



Advantages

The test is designed to:

- 1- Predict the risk of Meniere's disease.
- 2- Predict the response to treatment.



Classification

Area: Diagnostic
Pathology: Genetic and odd diseases.